ArticleOncotarget2018
Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in
Open access · diamondAbstract read
In one paragraph
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- CREB1 and GSK3 Isoforms as Potential Adaptive Signaling Nodes in PI3K/Akt/mTOR Inhibitor Treated Philadelphia Chromosome-Positive B-ALL.International journal of molecular sciences · 2026Article
- Research progress on the mechanisms of CSF3R mutations in leukemogenesis and treatment strategies.Cancer cell international · 2025Review
- Targeting senescent stemlike subpopulations in Philadelphia chromosome-like acute lymphoblastic leukemia.Blood · 2025Article
- Review
- Philadelphia chromosome-like acute lymphoblastic leukemia with concomitant rearrangements of CRLF2 and ABL1: a pediatric case report.BMC pediatrics · 2024Article
- Increased AID results in mutations at the CRLF2 locus implicated in Latin American ALL health disparities.Nature communications · 2024Article
- The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia.Annals of hematology · 2023Article
- Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.Leukemia · 2023Article
- Circulating Biomarkers Associated with the Diagnosis and Prognosis of B-Cell Progenitor Acute Lymphoblastic Leukemia.Cancers · 2023Review
- Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article.Annals of hematology · 2023Review
- Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia.Frontiers in oncology · 2023Article
- Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.Signal transduction and targeted therapy · 2022Article
- Article
- Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?Best practice & research. Clinical haematology · 2021Review
- Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.Scientific reports · 2021Article
- Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.Leukemia · 2021Article
- [Prognostic analysis of patients with mutations in the JAK/STAT signaling pathway in adult acute lymphoblastic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Genetics and Diagnostic Approach to Lymphoblastic Leukemia/Lymphoma.Cancer treatment and research · 2021Article
- Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia.Frontiers in oncology · 2021Article
- New Approaches to Treating Challenging Subtypes of ALL in AYA Patients.Current hematologic malignancy reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 9 institutions in 3 countries.
Qi Zhang *Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Ce Shi *Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Lina HanDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Nitin JainDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Kathryn G RobertsDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Helen MaDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Tianyu CaiDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Antonio CavazosDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Yoko TabeDepartment of Next Generation Hematology Laboratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Rodrigo O JacamoDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Hong MuDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Yang ZhaoDepartment of Bioinformatics & Comp Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Jing WangDepartment of Bioinformatics & Comp Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Shuo-Chieh WuDepartment of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA, USA.
Fenglin CaoDepartment of Hematology, The First Hospital Affiliated Harbin Medical University, Harbin, China.
Zhihong ZengDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Jin ZhouDepartment of Hematology, The First Hospital Affiliated Harbin Medical University, Harbin, China.
Yingchang MiDepartment of Leukemia, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China.
Elias J JabbourDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Ross LevineHematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sarah K TasianDivision of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
David M WeinstockDepartment of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA, USA.
David A FrumanDepartment of Molecular Biology & Biochemistry, University of California, Irvine, Irvine, CA, USA.
Marina KonoplevaDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USDana-Farber Cancer Institute · USHarbin Medical University · CNSt. Jude Children's Research Hospital · USChildren's Hospital of Philadelphia · USJuntendo University · JPMemorial Sloan Kettering Cancer Center · USPeking Union Medical College Hospital · CNUniversity of California, Irvine · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MPI3K Pathway Inhibition for Philadelphia-Like Acute Lymphoblastic LeukemiaK08CA184418 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI TASIAN, SARAH KATHLEEN · 2014 to 2018
$848kCombination strategies to enhance therapy for Ph-like B-ALLR21HD081319 · NICHD · UNIVERSITY OF CALIFORNIA-IRVINE · PI FRUMAN, DAVID ALEXANDER, KONOPLEVA, MARINA Y · 2015 to 2016
$459kNCI NIH HHS K08 CA184418NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA021765NICHD NIH HHS R21 HD081319
Abstract
Patients with cytokine receptor-like factor 2 rearranged (
Indexed as
JAKmTORPh-like ALL
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.